Showing results (631-640 of 3,150) with videos related to

Sort By:
Pageof 315
Neuro-Oncology|June 20, 2012
18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumabRobert J Harris, Timothy F Cloughesy, Whitney B Pope, et al.
Neuro-Oncology|July 4, 2012
RNAi-mediated inhibition of presenilin 2 inhibits glioma cell growth and invasion and is involved in the regulation of Nrg1/ErbB signalingBei Liu, Liang Wang, Liang-Liang Shen, et al.
Neuro-Oncology|July 4, 2012
PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcomeSabine Mueller, Joanna Phillips, Arzu Onar-Thomas, et al.
Neuro-Oncology|June 28, 2012
Incidence, treatment and survival of patients with craniopharyngioma in the surveillance, epidemiology and end results programBrad E Zacharia, Samuel S Bruce, Hannah Goldstein, et al.
Neuro-Oncology|March 24, 2010
Allergy and inflammatory transcriptome is predominantly negatively correlated with CD133 expression in glioblastomaJudith A Schwartzbaum, Kun Huang, Sean Lawler, et al.
Neuro-Oncology|March 24, 2010
In vivo validation of MRI vessel caliber index measurement methods with intravital optical microscopy in a U87 mouse brain tumor modelChristian T Farrar, Walid S Kamoun, Carsten D Ley, et al.
Neuro-Oncology|March 24, 2010
Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II studyAlexandre Carpentier, Philippe Metellus, Renata Ursu, et al.
Neuro-Oncology|February 15, 2015
Posttranscriptional deregulation of signaling pathways in meningioma subtypes by differential expression of miRNAsNicole Ludwig, Yoo-Jin Kim, Sabine C Mueller, et al.
Neuro-Oncology|February 11, 2015
Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastomaUlrik Lassen, Olivier L Chinot, Catherine McBain, et al.
Neuro-Oncology|April 14, 2022
Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trialAntonio Omuro, Alba A Brandes, Antoine F Carpentier, et al.
Pageof 315